Millennium Management’s Axsome Therapeutics AXSM Stock Holding History

Millennium Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-118,800	Closed	-$10.1M	–	5847
2024 Q4	$10.1M	Buy	118,800 +86,400	+267%	+$7.95M	﹤0.01%	2173
2024 Q3	$2.91M	Buy	+32,400	New	+$2.83M	﹤0.01%	3348
2024 Q2	–	Sell	-12,100	Closed	-$966K	–	5873
2024 Q1	$966K	Sell	12,100 -9,100	-43%	-$764K	﹤0.01%	4324
2023 Q4	$1.69M	Buy	21,200 +17,200	+430%	+$1.15M	﹤0.01%	3747
2023 Q3	$280K	Sell	4,000 -200	-5%	-$15K	﹤0.01%	4968
2023 Q2	$302K	Buy	+4,200	New	+$310K	﹤0.01%	4881
2021 Q4	–	Sell	-293,900	Closed	-$9.69M	–	6775
2021 Q3	$9.69M	Buy	+293,900	New	+$11.5M	0.01%	2094
2021 Q2	–	Sell	-25,000	Closed	-$1.42M	–	6516
2021 Q1	$1.42M	Buy	25,000 +16,000	+178%	+$1.13M	﹤0.01%	3854
2020 Q4	$733K	Buy	+9,000	New	+$673K	﹤0.01%	3935
2020 Q1	–	Sell	-50,000	Closed	-$5.17M	–	3830
2019 Q4	$5.17M	Buy	+50,000	New	+$2.02M	0.01%	1899
2019 Q2	–	Sell	-179,500	Closed	-$2.55M	–	4043
2019 Q1	$2.55M	Buy	+179,500	New	+$1.67M	﹤0.01%	2246

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's AXSM Position: Q1 2026 in Review

Millennium Management reduced its Axsome Therapeutics (AXSM) stake by 39% in Q1 2026, selling an estimated $2.28M and leaving 20,758 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

Millennium Management first reported a position in AXSM in Q4 2015 and has held it in 35 quarters since. The position peaked at $72.4M in Q4 2023. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Millennium Management held 20,758 shares of Axsome Therapeutics worth $3.51M as of Q1 2026.
Millennium Management sold 13,179 Axsome Therapeutics shares in Q1 2026, an estimated $2.28M.
Axsome Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3319 holding.
Millennium Management first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 35 quarters since.
Millennium Management's Axsome Therapeutics position peaked at $72.4M in Q4 2023.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.